Identifying and treating high-risk/MRD positive newly diagnosed multiple myeloma

Share :
Published: 29 Oct 2021
Views: 961
Prof Wee Joo Chng - National University Cancer Institute, Singapore

Prof Wee Joo Chng speaks to ecancer about his interactive session at the virtual Myeloma Knowledge Exchange (MyKE Myeloma) 2021 meeting on cases of high-risk/MRD positive and standard-risk/MRD negative newly diagnosed multiple myeloma (NDMM).

He starts by explaining the interactive format of the session before discussing the distinction between high-risk and standard-risk NDMM patients.

Prof Chng talks about the identification of high-risk patients, how to then approach their treatment and the future of treatment for these patients. He suggests that now is a good time to re-establish a set of criteria that can be uniformly applied to determine risk.

He discusses MRD-negative response as a key treatment objective and the currently unanswered questions around 'MRD adapted treatment' in terms of dose intensification or potency. He concludes by discussing his personal approach to NDMM patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.